Last reviewed · How we verify
NCT06042400
Trial of Written Exposure for Metastatic Cancer Patients (EASE)
NA trial testing Written Exposure Therapy in Metastatic Cancer in 30 participants. Completed in 21 September 2023.
21 September 2023
Quick facts
| Lead sponsor | University of Colorado, Boulder |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 30 |
| Start date | 18 April 2022 |
| Primary completion | 21 September 2023 |
| Estimated completion | 21 September 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Written Exposure Therapy
Conditions studied
- Metastatic Cancer — all drugs for Metastatic Cancer →
- Solid Tumor Cancer — all drugs for Solid Tumor Cancer →
- Lymphoproliferative Disorders — all drugs for Lymphoproliferative Disorders →
- Anxiety — all drugs for Anxiety →
Sponsor
University of Colorado, Boulder
Who can join
18 and older, any sex, with Metastatic Cancer or Solid Tumor Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In the face of imminent loss, many adults with metastatic cancer report a range of mental health challenges, including cancer-related trauma symptoms, fear of cancer progression and dying/death, anxiety, depression, and hopelessness, as well as physical symptoms such as fatigue and pain. Cancer patients may report feeling upset or haunted by imagined scenarios in a way that causes them distress and lowers their quality of life. This study aims to look at the acceptability and feasability of a writing-based intervention for adults with late-stage or recurrent cancer, or actively treated blood cancer. The EASE study uses a writing-based approach to address an individual's worst-case scenario about cancer because previous studies have shown that similar approaches have shown promise in reducing fear in early-stage cancer survivors and among adults with PTSD (posttraumatic stress disorder). The EASE study represents a novel adaptation of this foundational work on written exposure therapy (WET) to address worst-case scenarios among adults with late stage cancers. The EASE study will include 5 weekly one-on-one online video sessions with a trained therapist where participants will be coached through writing exercises based on a worst-case scenario related to their cancer experience.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06042400
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Written Exposure Therapy
Trials testing the same drug.
- NCT07498257 — Adaptation and Randomized Controlled Trial of Written Exposure Therapy for Adolescents · NA · not yet recruiting
- NCT07108608 — Adaptation of Written Exposure Therapy in Substance Treatment · NA · not yet recruiting
- NCT06771817 — Empowering Perinatal Adolescents Through Writing · NA · recruiting
- NCT06571513 — Written Exposure Therapy to Improve Recovery Among Sexual Assault Survivors · NA · completed
- NCT05674617 — PTSD Treatment for Veterans With Serious Mental Illness to Improve Functional Outcomes · NA · recruiting
Other recruiting trials for Metastatic Cancer
Currently open trials in the same condition.
- NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
- NCT07144085 — Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. · Phase 1 · recruiting
- NCT06963723 — Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer · NA · recruiting
- NCT06311851 — Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases · Phase 1, PHASE2 · recruiting
- NCT07011862 — COBRA: Cancer, Older Adults, Balance and Resistance Activities · NA · recruiting
Other University of Colorado, Boulder trials
Trials by the same sponsor.
- NCT07527338 — Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use · Phase 2, PHASE3 · not yet recruiting
- NCT07011160 — Neural Substrates Underlying Adaptations in Manual Dexterity of Older Adults · NA · not yet recruiting
- NCT07127965 — Exercise Adherence and Cognitive Decline: Phase 2 · NA · recruiting
- NCT06588582 — Perceptual Influences From Smoking Cannabis: an Experimental Study · NA · recruiting
- NCT06769022 — Exercise Adherence and Cognitive Decline · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06042400 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Boulder
- Last refreshed: 5 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06042400.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing